Skip to main content
. 2021 May 30;11(6):999. doi: 10.3390/diagnostics11060999

Table 4.

The predictive risk of CCA and BBD relative to normal control group by using level of cfDNA, CA19-9 and CEA.

Comparative Diagnosis Biomarkers Crude Adjusted
OR (95% CI) p-Value OR * (95% CI) p-Value
Normal vs. CCA cfDNA < 0.2175 vs. ≥ 0.2175 ng/µL 227.86 (26.73–1942.52) <0.0001 227.05 (25.93–1988.27) <0.0001
Normal vs. BBD cfDNA < 0.0897 vs. ≥ 0.0897 ng/µL 32.86 (7.65–141.13) <0.0001 101.46 (10.70–961.76) <0.0001
BBD vs. CCA cfDNA < 0.3388 vs. ≥ 0.3388 ng/µL 6.29 (2.44–16.26) <0.0001 7.649 (2.72–21.50) <0.0001
BBD vs. CCA CA19-9 < 39.90 vs. ≥ 39.90 U/mL 2.30 (0.94–5.62) 0.068 2.18 (0.86–5.46) 0.099
BBD vs. CCA CEA < 2.53 vs. ≥ 2.53 ng/mL 0.61 (0.26–1.42) 0.251 0.56 (0.23–1.37) 0.204

* Odds ratio adjusted for age and sex statistical analysis. Abbreviations; OR: odds ratio, CI: confidence interval, CCA: cholangiocarcinoma, BBD: benign biliary disease. A p-value < 0.05 was considered statistically significant.